collection
MENU ▼
Read by QxMD icon Read
search

DPP-4 inhibitors

shared collection
5 papers 0 to 25 followers
By Ehud Ur Professor and Head, Endocrinology, UBC, Vancouver
https://www.readbyqxmd.com/read/26628419/alogliptin-a-dipeptidyl-peptidase-4-inhibitor-prevents-the-progression-of-carotid-atherosclerosis-in-patients-with-type-2-diabetes-the-study-of-preventive-effects-of-alogliptin-on-diabetic-atherosclerosis-spead-a
#1
RANDOMIZED CONTROLLED TRIAL
Tomoya Mita, Naoto Katakami, Hidenori Yoshii, Tomio Onuma, Hideaki Kaneto, Takeshi Osonoi, Toshihiko Shiraiwa, Keisuke Kosugi, Yutaka Umayahara, Tsunehiko Yamamoto, Hiroki Yokoyama, Nobuichi Kuribayashi, Hideaki Jinnouchi, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada
OBJECTIVE: Recent experimental studies have shown that dipeptidyl peptidase 4 (DPP-4) inhibitors have antiatherosclerotic benefits in glucagon-like peptide 1-dependent and -independent manners. The current study investigated the effects of alogliptin, a DPP-4 inhibitor, on the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: This prospective, randomized, open-label, blinded-end point, multicenter, parallel-group, comparative study included 341 patients with T2DM free of a history of apparent cardiovascular diseases recruited at 11 clinical units and randomly allocated to treatment with alogliptin (n = 172) or conventional treatment (n = 169)...
January 2016: Diabetes Care
https://www.readbyqxmd.com/read/25552421/saxagliptin-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and-moderate-or-severe-renal-impairment-observations-from-the-savor-timi-53-trial
#2
RANDOMIZED CONTROLLED TRIAL
Jacob A Udell, Deepak L Bhatt, Eugene Braunwald, Matthew A Cavender, Ofri Mosenzon, Ph Gabriel Steg, Jaime A Davidson, Jose C Nicolau, Ramon Corbalan, Boaz Hirshberg, Robert Frederich, KyungAh Im, Amarachi A Umez-Eronini, Ping He, Darren K McGuire, Lawrence A Leiter, Itamar Raz, Benjamin M Scirica
OBJECTIVE: The glycemic management of patients with type 2 diabetes mellitus (T2DM) and renal impairment is challenging, with few treatment options. We investigated the effect of saxagliptin in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 trial according to baseline renal function. RESEARCH DESIGN AND METHODS: Patients with T2DM at risk for cardiovascular events were stratified as having normal or mildly impaired renal function (estimated glomerular filtration rate [eGFR] >50 mL/min/1...
April 2015: Diabetes Care
https://www.readbyqxmd.com/read/25205143/incretin-based-drugs-and-the-risk-of-congestive-heart-failure
#3
Oriana Hoi Yun Yu, Kristian B Filion, Laurent Azoulay, Valerie Patenaude, Agnieszka Majdan, Samy Suissa
OBJECTIVE: To determine whether the use of incretin-based drugs, including GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, is associated with an increased risk of congestive heart failure (CHF) among patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: The U.K. Clinical Practice Research Datalink, linked to the Hospital Episode Statistics database, was used to conduct a cohort study with a nested case-control analysis among patients newly prescribed antidiabetic drugs between 1 January 2007 and 31 March 2012 and no prior history of CHF...
February 2015: Diabetes Care
https://www.readbyqxmd.com/read/25583754/combination-of-empagliflozin-and-linagliptin-as-second-line-therapy-in-subjects-with-type-2-diabetes-inadequately-controlled-on-metformin
#4
RANDOMIZED CONTROLLED TRIAL
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl
OBJECTIVE: To evaluate the efficacy and safety of combinations of empagliflozin/linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. RESEARCH DESIGN AND METHODS: Subjects were randomized to a combination of empagliflozin 25 mg/linagliptin 5 mg (n = 137), empagliflozin 10 mg/linagliptin 5 mg (n = 136), empagliflozin 25 mg (n = 141), empagliflozin 10 mg (n = 140), or linagliptin 5 mg (n = 132) as add-on to metformin for 52 weeks...
March 2015: Diabetes Care
https://www.readbyqxmd.com/read/25216328/pharmacology-physiology-and-mechanisms-of-action-of-dipeptidyl-peptidase-4-inhibitors
#5
REVIEW
Erin E Mulvihill, Daniel J Drucker
Dipeptidyl peptidase-4 (DPP4) is a widely expressed enzyme transducing actions through an anchored transmembrane molecule and a soluble circulating protein. Both membrane-associated and soluble DPP4 exert catalytic activity, cleaving proteins containing a position 2 alanine or proline. DPP4-mediated enzymatic cleavage alternatively inactivates peptides or generates new bioactive moieties that may exert competing or novel activities. The widespread use of selective DPP4 inhibitors for the treatment of type 2 diabetes has heightened interest in the molecular mechanisms through which DPP4 inhibitors exert their pleiotropic actions...
December 2014: Endocrine Reviews
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"